Consistently, daratumumab, a monoclonal antibody against CD38, reacted with CD38 expressed on monocytes and inhibited in vitro osteoclastogenesis and bone resorption of mononuclear cells harvested from the bone marrow of multiple myeloma patients (Costa et al., 2017). This evidence concerns the gene CD38 and plasma cell myeloma.